Subscribe to RSS
DOI: 10.1055/s-0028-1101270
Host–Environment Interactions in Exposure-Related Diffuse Lung Diseases
Publication History
Publication Date:
16 February 2009 (online)
ABSTRACT
Diffuse lung disease (DLD), also known as interstitial lung disease (ILD), comprises a group of relatively rare but devastating lung diseases that involve varying degrees of acute and chronic inflammation, and which may present with end-stage fibroproliferation. There are currently no proven therapeutic strategies to halt progression of DLDs. Thinking about DLDs has evolved over time from hypotheses invoking inflammation as the prime mover in the etiology of disease, to the current hypothesis that interactions between a damaged and frustrated epithelium, and the response of underlying mesenchymal cells that takes place, contribute to the fibroproliferative milieu. The greatest challenge to understanding the role of environmental exposures in pathogenesis of DLDs is that there is no clear consensus on the etiology and pathogenesis of these diseases. Emerging data on the relationship between loss of epithelial integrity and mesenchymal fibroproliferation support the hypothesis that the damage to the epithelium is a critical component in the development of DLDs that progress to a fibroproliferative presentation. Thus it follows that environmental stress which impacts the well-being of the epithelium may play a critical role in shifting the balance of lung homeostasis through ongoing insult as a result of exposure to environmental agents. Animal models that recapitulate the vulnerable epithelium observed in patients who develop fibrotic lung disease associated with DLDs will provide the best opportunity to understand mechanisms associated with the etiology of these diseases.
KEYWORDS
Vulnerable epithelium - interstitial lung disease - fibrosis
REFERENCES
- 1 Pitcher W D. Hypersensitivity pneumonitis. Am J Med Sci. 1990; 300 251-266
- 2 Wild L G, Lopez M. Hypersensitivity pneumonitis: a comprehensive review. J Investig Allergol Clin Immunol. 2001; 11 3-15
- 3 Moore J E, Convery R P, Millar B C, Rao J R, Elborn J S. Hypersensitivity pneumonitis associated with mushroom worker's lung: an update on the clinical significance of the importation of exotic mushroom varieties. Int Arch Allergy Immunol. 2005; 136 98-102
- 4 Galland C, Reynaud C, De Haller R, Polla B S, Leuenberger P. Cheese-washer's disease: a current stable form of extrinsic allergic alveolitis in a rural setting. Rev Mal Respir. 1991; 8 381-386
- 5 American Thoracic Society . Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med. 2000; 161(2 Pt 1) 646-664
- 6 Nicholson A G, Florio R, Hansell D M et al.. Pulmonary involvement by Niemann–Pick disease: a report of six cases. Histopathology. 2006; 48 596-603
- 7 Mendelson D S, Wasserstein M P, Desnick R J et al.. Type B Niemann-Pick disease: findings at chest radiography, thin-section CT, and pulmonary function testing. Radiology. 2006; 238 339-345
- 8 Knight S, Vulliamy T, Copplestone A, Gluckman E, Mason P, Dokal I. Dyskeratosis Congenita (DC) Registry: identification of new features of DC. Br J Haematol. 1998; 103 990-996
- 9 Selman M, King T E, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med. 2001; 134 136-151
- 10 Noble P W, Homer R J. Back to the future: historical perspective on the pathogenesis of idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol. 2005; 33 113-120
- 11 Baptista A L, Parra E R, Filho J V, Kairalla R A, de Carvalho C R, Capelozzi V L. Structural features of epithelial remodeling in usual interstitial pneumonia histologic pattern. Lung. 2006; 184 239-244
- 12 Chilosi M, Poletti V, Murer B et al.. Abnormal re-epithelialization and lung remodeling in idiopathic pulmonary fibrosis: the role of deltaN-p63. Lab Invest. 2002; 82 1335-1345
- 13 Garantziotis S, Schwartz D A. Host–environment interactions in pulmonary fibrosis. Semin Respir Crit Care Med. 2006; 27 574-580
- 14 Baumgartner K B, Samet J M, Coultas D B et al.. Occupational and environmental risk factors for idiopathic pulmonary fibrosis: a multicenter case-control study. Collaborating Centers. Am J Epidemiol. 2000; 152 307-315
- 15 Hubbard R, Lewis S, Richards K, Johnston I, Britton J. Occupational exposure to metal or wood dust and aetiology of cryptogenic fibrosing alveolitis. Lancet. 1996; 347 284-289
- 16 Hubbard R, Cooper M, Antoniak M et al.. Risk of cryptogenic fibrosing alveolitis in metal workers. Lancet. 2000; 355 466-467
- 17 Baumgartner K B, Samet J M, Stidley C A, Colby T V, Waldron J A. Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1997; 155 242-248
- 18 Schwartz D A, Van Fossen D S, Davis C S et al.. Determinants of progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1994; 149(2 Pt 1) 444-449
- 19 Steele M P, Speer M C, Loyd J E et al.. Clinical and pathologic features of familial interstitial pneumonia. Am J Respir Crit Care Med. 2005; 172 1146-1152
- 20 Iwai K, Mori T, Yamada N, Yamaguchi M, Hosoda Y. Idiopathic pulmonary fibrosis: epidemiologic approaches to occupational exposure. Am J Respir Crit Care Med. 1994; 150 670-675
- 21 Johnston I, Britton J, Kinnear W, Logan R. Rising mortality from cryptogenic fibrosing alveolitis. BMJ. 1990; 301 1017-1021
- 22 Brass D M, Hoyle G W, Poovey H G, Liu J Y, Brody A R. Reduced tumor necrosis factor-alpha and transforming growth factor-beta1 expression in the lungs of inbred mice that fail to develop fibroproliferative lesions consequent to asbestos exposure. Am J Pathol. 1999; 154 853-862
- 23 Spees J L, Pociask D A, Sullivan D E et al.. Engraftment of bone marrow progenitor cells in a rat model of asbestos-induced pulmonary fibrosis. Am J Respir Crit Care Med. 2007; 176 385-394
- 24 Coin P G, Osornio-Vargas A R, Roggli V L, Brody A R. Pulmonary fibrogenesis after three consecutive inhalation exposures to chrysotile asbestos. Am J Respir Crit Care Med. 1996; 154 1511-1519
- 25 Rivers D, Moris T G, Wise M E. The fibrogenicity of some respirable dusts measured in mice. Br J Ind Med. 1963; 20 13-23
- 26 Adamson I Y, Bowden D H. Role of polymorphonuclear leukocytes in silica-induced pulmonary fibrosis. Am J Pathol. 1984; 117 37-43
- 27 Brass D M, Savov J D, Gavett S H, Haykal-Coates N, Schwartz D A. Subchronic endotoxin inhalation causes persistent airway disease. Am J Physiol Lung Cell Mol Physiol. 2003; 285 L755-761
- 28 Hammond E C, Selikoff I J, Seidman H. Asbestos exposure, cigarette smoking and death rates. Ann N Y Acad Sci. 1979; 330 473-490
- 29 Adamson I Y, Bowden D H. Response of mouse lung to crocidolite asbestos, I: Minimal fibrotic reaction to short fibres. J Pathol. 1987; 152 99-107
- 30 Brass D M, Tsai S Y, Brody A R. Primary lung fibroblasts from the 129 mouse strain exhibit reduced growth factor responsiveness in vitro. Exp Lung Res. 2001; 27 639-653
- 31 Mac M J. Familial pulmonary fibrosis. Dis Chest. 1951; 20 426-436
- 32 Adelman A G, Chertkow G, Hayton R C. Familial fibrocystic pulmonary dysplasia: a detailed family study. Can Med Assoc J. 1966; 95 603-610
- 33 Barzo P. Familial idiopathic fibrosing alveolitis. Eur J Respir Dis. 1985; 66 350-352
- 34 Marshall R P, Puddicombe A, Cookson W O, Laurent G J. Adult familial cryptogenic fibrosing alveolitis in the United Kingdom. Thorax. 2000; 55 143-146
- 35 Peabody J W, Peabody Jr J W, Hayes E W, Hayes Jr E W. Idiopathic pulmonary fibrosis; its occurrence in identical twin sisters. Dis Chest. 1950; 18 330-344
- 36 Javaheri S, Lederer D H, Pella J A, Mark G J, Levine B W. Idiopathic pulmonary fibrosis in monozygotic twins: the importance of genetic predisposition. Chest. 1980; 78 591-594
- 37 Hodgson U, Pulkkinen V, Dixon M et al.. ELMOD2 is a candidate gene for familial idiopathic pulmonary fibrosis. Am J Hum Genet. 2006; 79 149-154
- 38 Selman M, Pardo A, Barrera L et al.. Gene expression profiles distinguish idiopathic pulmonary fibrosis from hypersensitivity pneumonitis. Am J Respir Crit Care Med. 2006; 173 188-198
- 39 Kelly M M, Leigh R, Gilpin S E et al.. Cell-specific gene expression in patients with usual interstitial pneumonia. Am J Respir Crit Care Med. 2006; 174 557-565
- 40 Pignatti P, Brunetti G, Moretto D et al.. Role of the chemokine receptors CXCR3 and CCR4 in human pulmonary fibrosis. Am J Respir Crit Care Med. 2006; 173 310-317
- 41 Jiang D, Liang J, Hodge J et al.. Regulation of pulmonary fibrosis by chemokine receptor CXCR3 . J Clin Invest. 2004; 114 291-299
- 42 Tager A M, Kradin R L, LaCamera P et al.. Inhibition of pulmonary fibrosis by the chemokine IP-10/CXCL10. Am J Respir Cell Mol Biol. 2004; 31 395-404
- 43 Burdick M D, Murray L A, Keane M P et al.. CXCL11 attenuates bleomycin-induced pulmonary fibrosis via inhibition of vascular remodeling. Am J Respir Crit Care Med. 2005; 171 261-268
- 44 Belperio J A, Dy M, Murray L et al.. The role of the Th2 CC chemokine ligand CCL17 in pulmonary fibrosis. J Immunol. 2004; 173 4692-4698
- 45 Yang I V, Burch L H, Steele M P et al.. Gene expression profiling of familial and sporadic interstitial pneumonia. Am J Respir Crit Care Med. 2007; 175 45-54
- 46 Nogee L M, Dunbar III A E, Wert S E, Askin F, Hamvas A, Whitsett J A. A mutation in the surfactant protein C gene associated with familial interstitial lung disease. N Engl J Med. 2001; 344 573-579
- 47 Nogee L M, Dunbar III A E, Wert S, Askin F, Hamvas A, Whitsett J A. Mutations in the surfactant protein C gene associated with interstitial lung disease. Chest. 2002; 121(3, Suppl) 20S-21S
- 48 Cameron H S, Somaschini M, Carrera P et al.. A common mutation in the surfactant protein C gene associated with lung disease. J Pediatr. 2005; 146 370-375
- 49 Thomas A Q, Lane K, Phillips III J et al.. Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred. Am J Respir Crit Care Med. 2002; 165 1322-1328
- 50 Tredano M, Griese M, Brasch F et al.. Mutation of SFTPC in infantile pulmonary alveolar proteinosis with or without fibrosing lung disease. Am J Med Genet A. 2004; 126A 18-26
- 51 Stevens P A, Pettenazzo A, Brasch F et al.. Nonspecific interstitial pneumonia, alveolar proteinosis, and abnormal proprotein trafficking resulting from a spontaneous mutation in the surfactant protein C gene. Pediatr Res. 2005; 57 89-98
- 52 Wang W J, Mulugeta S, Russo S J, Beers M F. Deletion of exon 4 from human surfactant protein C results in aggresome formation and generation of a dominant negative. J Cell Sci. 2003; 116(Pt 4) 683-692
- 53 Mulugeta S, Nguyen V, Russo S J, Muniswamy M, Beers M F. A surfactant protein C precursor protein BRICHOS domain mutation causes endoplasmic reticulum stress, proteasome dysfunction, and caspase 3 activation. Am J Respir Cell Mol Biol. 2005; 32 521-530
- 54 Mulugeta S, Maguire J A, Newitt J L, Russo S J, Kotorashvili A, Beers M F. Misfolded BRICHOS SP-C mutant proteins induce apoptosis via caspase-4- and cytochrome c-related mechanisms. Am J Physiol Lung Cell Mol Physiol. 2007; 293 L720-729
- 55 Lawson W E, Grant S W, Ambrosini V et al.. Genetic mutations in surfactant protein C are a rare cause of sporadic cases of IPF. Thorax. 2004; 59 977-980
- 56 Armanios M Y, Chen J J, Cogan J D et al.. Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med. 2007; 356 1317-1326
- 57 Tsakiri K D, Cronkhite J T, Kuan P J et al.. Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci U S A. 2007; 104 7552-7557
- 58 Morla M, Busquets X, Pons J, Sauleda J, MacNee W, Agusti A G. Telomere shortening in smokers with and without COPD. Eur Respir J. 2006; 27 525-528
- 59 Bowzard J B, Cheng D, Peng J, Kahn R A. ELMOD2 is an Arl2 GTPase-activating protein that also acts on Arfs. J Biol Chem. 2007; 282 17568-17580
- 60 Pierson D M, Ionescu D, Qing G et al.. Pulmonary fibrosis in Hermansky–Pudlak syndrome. a case report and review. Respiration. 2006; 73 382-395
- 61 Nakatani Y, Nakamura N, Sano J et al.. Interstitial pneumonia in Hermansky–Pudlak syndrome: significance of florid foamy swelling/degeneration (giant lamellar body degeneration) of type-2 pneumocytes. Virchows Arch. 2000; 437 304-313
- 62 Tang X, Yamanaka S, Miyagi Y, Nagashima Y, Nakatani Y. Lung pathology of pale ear mouse (model of Hermansky–Pudlak syndrome 1) and beige mouse (model of Chediak–Higashi syndrome): severity of giant lamellar body degeneration of type II pneumocytes correlates with interstitial inflammation. Pathol Int. 2005; 55 137-143
- 63 Lyerla T A, Rusiniak M E, Borchers M et al.. Aberrant lung structure, composition, and function in a murine model of Hermansky–Pudlak syndrome. Am J Physiol Lung Cell Mol Physiol. 2003; 285 L643-653
- 64 Liu J Y, Morris G F, Lei W H, Hart C E, Lasky J A, Brody A R. Rapid activation of PDGF-A and -B expression at sites of lung injury in asbestos-exposed rats. Am J Respir Cell Mol Biol. 1997; 17 129-140
- 65 Young L R, Pasula R, Gulleman P M, Deutsch G H, McCormack F X. Susceptibility of Hermansky–Pudlak mice to bleomycin-induced type II cell apoptosis and fibrosis. Am J Respir Cell Mol Biol. 2007; 37 67-74
- 66 Riccardi V M. Von Recklinghausen neurofibromatosis. N Engl J Med. 1981; 305 1617-1627
- 67 Zamora A C, Collard H R, Wolters P J, Webb W R, King T E. Neurofibromatosis-associated lung disease: a case series and literature review. Eur Respir J. 2007; 29 210-214
- 68 Ryu J H, Parambil J G, McGrann P S, Aughenbaugh G L. Lack of evidence for an association between neurofibromatosis and pulmonary fibrosis. Chest. 2005; 128 2381-2386
- 69 Patchefsky A S, Atkinson W G, Hoch W S, Gordon G, Lipshitz H I. Interstitial pulmonary fibrosis and von Recklinghausen's disease: an ultrastructural and immunofluorescent study. Chest. 1973; 64 459-464
- 70 Ikegami M, Dhami R, Schuchman E H. Alveolar lipoproteinosis in an acid sphingomyelinase-deficient mouse model of Niemann–Pick disease. Am J Physiol Lung Cell Mol Physiol. 2003; 284 L518-525
- 71 Schneider E L, Epstein C J, Kaback M J, Brandes D. Severe pulmonary involvement in adult Gaucher's disease: report of three cases and review of the literature. Am J Med. 1977; 63 475-480
- 72 Xu Y H, Quinn B, Witte D, Grabowski G A. Viable mouse models of acid beta-glucosidase deficiency: the defect in Gaucher disease. Am J Pathol. 2003; 163 2093-2101
- 73 Sun Y, Quinn B, Witte D P, Grabowski G A. Gaucher disease mouse models: point mutations at the acid beta-glucosidase locus combined with low-level prosaposin expression lead to disease variants. J Lipid Res. 2005; 46 2102-2113
- 74 Auwerx J, Demedts M, Bouillon R, Desmet J. Coexistence of hypocalciuric hypercalcaemia and interstitial lung disease in a family: a cross-sectional study. Eur J Clin Invest. 1985; 15 6-14
- 75 Demedts M, Auwerx J, Goddeeris P, Bouillon R, Gyselen A, Lauweryns J. The inherited association of interstitial lung disease, hypocalciuric hypercalcemia, and defective granulocyte function. Am Rev Respir Dis. 1985; 131 470-475
- 76 Ho C, Conner D A, Pollak M R et al.. A mouse model of human familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Nat Genet. 1995; 11 389-394
David M BrassPh.D.
DUMC Box 3373, Research Drive
Durham, NC 27710
Email: David.brass@duke.edu